# Staar Surgical Co: overview

STAA · Nasdaq · CIK 718937 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jan 2

Pages: [Overview](/companies/staa.md) · [Financials](/companies/staa/financials.md) · [Filings](/companies/staa/filings.md) · [Insiders](/companies/staa/insiders.md)

Latest reported revenue: [$93.5m](/filings/0000718937-26-000037.md) for Q2 FY2026, three months to 2026-07-03, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:Revenues, accession 0000718937-26-000037).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2026-01-02) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [88.6](/filings/0001193125-25-266879.md) | [49.0 d](/filings/0000718937-26-000004.md) | [42.6](/filings/0000718937-26-000023.md) | [44.3](/filings/0000718937-26-000037.md) | [94.7](/filings/0001193125-25-266879.md) | [57.8 d](/filings/0000718937-26-000004.md) | [93.5](/filings/0000718937-26-000023.md) | [93.5](/filings/0000718937-26-000037.md) |
| Gross margin | % | [77.3%](/filings/0001193125-25-266879.md) | [64.7% d](/filings/0000718937-26-000004.md) | [65.8%](/filings/0000718937-26-000023.md) | [74.0%](/filings/0000718937-26-000037.md) | [82.2%](/filings/0001193125-25-266879.md) | [75.7% d](/filings/0000718937-26-000004.md) | [73.6%](/filings/0000718937-26-000023.md) | [74.5%](/filings/0000718937-26-000037.md) |
| Operating margin | % | [6.4%](/filings/0001193125-25-266879.md) | [(57.0%) d](/filings/0000718937-26-000004.md) | [(134.8%)](/filings/0000718937-26-000023.md) | [(67.6%)](/filings/0000718937-26-000037.md) | [19.5%](/filings/0001193125-25-266879.md) | [(39.5%) d](/filings/0000718937-26-000004.md) | [8.5%](/filings/0000718937-26-000023.md) | [10.8%](/filings/0000718937-26-000037.md) |
| Net margin | % | [11.3%](/filings/0001193125-25-266879.md) | [(69.9%) d](/filings/0000718937-26-000004.md) | [(127.3%)](/filings/0000718937-26-000023.md) | [(37.9%)](/filings/0000718937-26-000037.md) | [9.4%](/filings/0001193125-25-266879.md) | [(31.7%) d](/filings/0000718937-26-000004.md) | [5.6%](/filings/0000718937-26-000023.md) | [8.6%](/filings/0000718937-26-000037.md) |
| Diluted EPS | $ per share | [0.20](/filings/0001193125-25-266879.md) | not reported | [(1.10)](/filings/0000718937-26-000023.md) | [(0.34)](/filings/0000718937-26-000037.md) | [0.18](/filings/0001193125-25-266879.md) | not reported | [0.10](/filings/0000718937-26-000023.md) | [0.16](/filings/0000718937-26-000037.md) |
| Free cash flow | $m | [(2.4) d](/filings/0001193125-25-266879.md) | [(5.1) d](/filings/0000718937-26-000004.md) | [(7.2)](/filings/0000718937-26-000023.md) | [(29.0) d](/filings/0000718937-26-000037.md) | [1.8 d](/filings/0001193125-25-266879.md) | [(5.6) d](/filings/0000718937-26-000004.md) | [(22.1)](/filings/0000718937-26-000023.md) | [19.2 d](/filings/0000718937-26-000037.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-30) | FY2023 (2023-12-29) | FY2024 (2024-12-27) | FY2025 (2026-01-02) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [230](/filings/0000950170-24-020572.md) | [239](/filings/0000718937-26-000004.md) | [322](/filings/0000718937-26-000004.md) | [314](/filings/0000718937-26-000004.md) | [239](/filings/0000718937-26-000004.md) |
| Gross margin | % | [77.5%](/filings/0000950170-24-020572.md) | [93.3%](/filings/0000950170-25-024813.md) | [78.4%](/filings/0000718937-26-000004.md) | [76.3%](/filings/0000718937-26-000004.md) | [76.2%](/filings/0000718937-26-000004.md) |
| Operating margin | % | [14.5%](/filings/0000950170-24-020572.md) | [18.3%](/filings/0000950170-25-024813.md) | [8.7%](/filings/0000718937-26-000004.md) | [(4.0%)](/filings/0000718937-26-000004.md) | [(38.3%)](/filings/0000718937-26-000004.md) |
| Net margin | % | [11.9%](/filings/0000950170-23-058994.md) | [16.6%](/filings/0000950170-25-024813.md) | [6.6%](/filings/0000718937-26-000004.md) | [(6.4%)](/filings/0000718937-26-000004.md) | [(33.6%)](/filings/0000718937-26-000004.md) |
| Diluted EPS | $ per share | [0.56](/filings/0000950170-23-058994.md) | [0.80](/filings/0000950170-25-024813.md) | [0.43](/filings/0000718937-26-000004.md) | [(0.41)](/filings/0000718937-26-000004.md) | [(1.62)](/filings/0000718937-26-000004.md) |
| Free cash flow | $m | [30.3](/filings/0000950170-24-020572.md) | [17.6](/filings/0000950170-25-024813.md) | [(3.6)](/filings/0000718937-26-000004.md) | [(7.7)](/filings/0000718937-26-000004.md) | [(40.1)](/filings/0000718937-26-000004.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/staa/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BROADWOOD CAPITAL INC](/funds/1278387.md) | 2026-06-30 | $462.6m | 16,123,842 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $193.1m | 6,731,154 |  | Added +65,036 |
| [Madison Avenue Partners, LP](/funds/1801265.md) | 2026-06-30 | $119.8m | 4,175,748 |  | Added +1,734,070 |
| [Yunqi Capital Ltd](/funds/1912273.md) | 2026-06-30 | $93.4m | 3,257,130 |  | Unchanged |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $69.9m | 2,437,446 |  | Added +1,614,294 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $61.7m | 2,150,809 |  | Added +1,080,870 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $56.8m | 1,979,573 |  | Reduced −144,016 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $50.8m | 1,769,354 |  | Reduced −63,642 |
| [Anatole Investment Management Ltd](/funds/1693745.md) | 2026-06-30 | $47.4m | 1,651,701 |  | Added +50,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $44.5m | 1,552,743 |  | Reduced −137,863 |

## Recent filings

[All 1,316 filings](/companies/staa/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 12:25 ET | [8-K/A](/filings/0001193125-26-413763.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-413763 |
| 2026-09-10 | 17:37 ET | [8-K](/filings/0001193125-26-386662.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-386662 |
| 2026-08-12 | 16:05 ET | [10-Q](/filings/0000718937-26-000037.md) | Quarterly report, period 2026-07-03 | 0000718937-26-000037 |
| 2026-08-12 | 16:04 ET | [8-K](/filings/0000718937-26-000036.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000718937-26-000036 |
| 2026-08-06 | 11:04 ET | [8-K](/filings/0001193125-26-337197.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-337197 |
| 2026-06-22 | 16:05 ET | [8-K](/filings/0000718937-26-000029.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000718937-26-000029 |
| 2026-06-09 | 16:02 ET | [8-K](/filings/0000718937-26-000027.md) | 5.02 Departure or appointment of officers or directors | 0000718937-26-000027 |
| 2026-05-13 | 16:06 ET | [10-Q](/filings/0000718937-26-000023.md) | Quarterly report, period 2026-04-03 | 0000718937-26-000023 |
| 2026-05-13 | 16:02 ET | [8-K](/filings/0000718937-26-000022.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000718937-26-000022 |
| 2026-05-04 | 16:01 ET | [DEF 14A](/filings/0000718937-26-000015.md) | Proxy statement, period 2026-05-01 | 0000718937-26-000015 |

## Latest annual report

[Form 10-K for the fiscal year ended Jan 2, 2026](/filings/0000718937-26-000004.md), filed Mar 3, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 718937
- Tickers: STAA
- Exchange: Nasdaq
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:30 ET. No prices; not investment advice.